Pooled RCTs: Atorvastatin did not increase renal-related serious adverse events by Herrington, W, Haynes, R

Metformin: the safest hypoglycaemic agent in chronic kidney disease? by Nye, H, Herrington, W

Stroke risk in maintenance hemodialysis. by Herrington, W, Lewis, D

Contraindications to pharmacologic therapies for gout. by Lewis, D, Herrington, W

Tightening our understanding of intensive glycaemic control by Herrington, W, Preiss, D

Extreme ischaemic heart disease risk in people with type 1 diabetes by Herrington, W, Bragg, F

Kidney failure with a diagnostic chest radiograph. by Herrington, W, Lewis, D

Metformin use in chronic kidney disease: new evidence to guide dosing. by Herrington, W, Nye, H, Aung, T

Kidney disease trials for the 21st century: innovations in design and conduct by Herrington, W, Staplin, N, Haynes, R

Increasing the use of mobile technology-derived endpoints in clinical trials. by Herrington, W, Goldsack, J, Landray, M

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial by Herrington, W, Wanner, C, Green, JB

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial by Preiss, D, Herrington, W, Haynes, R

Authors' reply by Herrington, W, Donovan, K, Mihaylova, B

Are arterial and venous samples clinically equivalent for the estimation of pH, serum bicarbonate and potassium concentration in critically ill patients? by Herrington, W, Nye, H, Hammersley, MS, Watkinson, P

Acute treatment effects on GFR in randomized clinical trials of kidney disease progression by Neuen, B, Tighiouart, H, Heerspink, HJL, Herrington, W

The role of emerging risk factors in cardiovascular outcome by Lacey, B, Herrington, W, Preiss, D, Lewington, S, Armitage, J

Does prophylactic anticoagulation reduce the risk of femoral tunneled dialysis catheter-related complications? by Herrington, W, Nye, H, Haynes, R, Winearls, C, Vaux, E

The hyponatraemic hairdresser: highlighting the differentials. by Herrington, W, Al-Mossawi, M, Roberts, I, O'Callaghan, C

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease by Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P

Chronic kidney disease, heart failure and neprilysin inhibition by Haynes, R, Zhu, D, Judge, P, Herrington, W, Kalra, P, Baigent, C